Scientists test novel drug duos against tough lung cancer

NCT ID NCT03381274

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and effectiveness of new two-drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to previous treatments. The trial enrolled 43 participants to try different drug pairings, aiming to see if these combinations can better control the cancer. Researchers are looking at how well the tumors shrink and how long patients live without their cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

San Francisco, California, 94143, United States
Research Site

Aurora, Colorado, 80045, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Baltimore, Maryland, 21224, United States
Research Site

New York, New York, 10032, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Taichung, 40705, Taiwan

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG